FTC Homeopathic Disclaimer Policy Should Prompt FDA Changes – Advocacy Group
This article was originally published in The Pink Sheet
Executive Summary
Center for Inquiry reiterates its criticism of homeopathy and calls on FDA to step up vetting of US-marketed homeopathic products.